|Articles|June 15, 2002

BioPharm International

  • BioPharm International-06-01-2002
  • Volume 15
  • Issue 6

Business Matters: Is a Turnaround in Sight?

by G. Steven Burrill, Burrill & Company After a strong finish in 2001, biotech is back in the dumps.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 23 years ago

Negotiating and Structuring Strategic Alliances

over 23 years ago

Finding Funding in Biotechnology: Keeping the Companies Alive

over 23 years ago

Biotechnology Patent Holders Beware! A Supreme Court Ruling may Significantly Reduce the Value of Your Patent Portfolio

over 23 years ago

Guest Editorial: Enabling Collaboration in the Pharmaceutical Industry

over 23 years ago

Stem Cells and Xenotransplantation: Ethics, Patents, and Politics

over 23 years ago

Unlocking the Value of R&D: Managing the Risks

over 23 years ago

Viewpoint: United Kingdom highlights biomanufacturing capabilities

over 23 years ago

Creating Effective Biopharmaceutical QA/QC Organizations: Your People are the Key

over 23 years ago

Inside Washington: Safety, Risk, and Biotechnology Regulation

over 23 years ago

Criminal Penalties for Theft of Biological Material

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!